{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T01:25:58Z","timestamp":1785288358951,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"crossref","award":["R231-A13765"],"award-info":[{"award-number":["R231-A13765"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-14122-9","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T20:14:21Z","timestamp":1754943261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preliminary evaluation of ShallowHRD performance compared to HRDetect in familial breast cancer tumors"],"prefix":"10.1038","volume":"15","author":[{"given":"Louise","family":"Adel Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Hey","family":"Baekgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Bohnensack","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Eriksen","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Bak Jylling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab","family":"Hikmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"van Overeem Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge S\u00f8kilde","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Jakob","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"14122_CR1","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1093\/nar\/gks270","volume":"40","author":"L Krej\u010d\u00ed","year":"2012","unstructured":"Krej\u010d\u00ed, L., Altmannov\u00e1, V., \u0160p\u0131\u0301rek, M. & Zhao, X. Homologous recombination and its regulation. Nucleic Acids Res. 40, 5795\u20135818. https:\/\/doi.org\/10.1093\/nar\/gks270 (2012).","journal-title":"Nucleic Acids Res."},{"key":"14122_CR2","doi-asserted-by":"publisher","unstructured":"Zhao, W., Steinfeld, J. B., Liang, F., Chen, X., Maranon, D. G., Jian, C. et al. BRCA1\u2013BARD1 promotes RAD51-mediated homologous DNA pairing. Nature 550, 360\u2013365. https:\/\/doi.org\/10.1038\/nature24060 (2017).","DOI":"10.1038\/nature24060"},{"key":"14122_CR3","doi-asserted-by":"publisher","unstructured":"He, L., Gao, F., Zhu, J., Xu, Q., Yu, Q., Yang, M. et al. Homologous recombination deficiency serves as a prognostic biomarker in clear cell renal cell carcinoma. Exp. Ther. Med. 26. https:\/\/doi.org\/10.3892\/etm.2023.12128 (2023).","DOI":"10.3892\/etm.2023.12128"},{"key":"14122_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/jpm11070612","volume":"11","author":"S Wagener-Ryczek","year":"2021","unstructured":"Wagener-Ryczek, S., Merkelbach\u2010Bruse, S. & Siemanowski, J. Biomarkers for homologous recombination deficiency in cancer. J. Pers. Med. 11, 612. https:\/\/doi.org\/10.3390\/jpm11070612 (2021).","journal-title":"J. Pers. Med."},{"key":"14122_CR5","doi-asserted-by":"publisher","unstructured":"Bergstrom, E. N., Abbasi, A., D\u00edaz-Gay, M., Galland, L., Lippman, S. M., Ladoire, S. et al. Deep learning predicts HRD and platinum response from histology slides in breast and ovarian cancer 2023. Medrxiv https:\/\/doi.org\/10.1101\/2023.02.23.23285869","DOI":"10.1101\/2023.02.23.23285869"},{"key":"14122_CR6","doi-asserted-by":"publisher","first-page":"23899","DOI":"10.1074\/jbc.c000276200","volume":"275","author":"A Bhattacharyya","year":"2000","unstructured":"Bhattacharyya, A., Ear, U., Koller, B. H., Weichselbaum, R. R. & Bishop, D. K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899\u201323903. https:\/\/doi.org\/10.1074\/jbc.c000276200 (2000).","journal-title":"J. Biol. Chem."},{"key":"14122_CR7","doi-asserted-by":"publisher","unstructured":"Valenza, C., Trapani, D., Gandini, S., Sposetti, C., Boscolo Bielo, L., Marra, A. et al. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. Eur. J. Cancer. 190, 112944. https:\/\/doi.org\/10.1016\/j.ejca.2023.112944 (2023).","DOI":"10.1016\/j.ejca.2023.112944"},{"key":"14122_CR8","doi-asserted-by":"publisher","unstructured":"Zhao, E. Y., Shen, Y., Pleasance, E., Kasaian, K., Leelakumari, S., Jones, M. et al. Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer. Clin. Cancer Res. 23, 7521\u20137530. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1941 (2017).","DOI":"10.1158\/1078-0432.CCR-17-1941"},{"key":"14122_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11523-021-00796-4","volume":"16","author":"L Cortesi","year":"2021","unstructured":"Cortesi, L., Rugo, H. S. & Jackisch, C. An overview of PARP inhibitors for the treatment of breast cancer. Target. Oncol. 16, 255\u2013282. https:\/\/doi.org\/10.1007\/s11523-021-00796-4 (2021).","journal-title":"Target. Oncol."},{"key":"14122_CR10","doi-asserted-by":"publisher","unstructured":"Cunningham, J. M., Cicek, M. S., Larson, N. B., Davila, J., Wang, C., Larson, M. C. et al. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2 and RAD51C status. Sci. Rep. 4 https:\/\/doi.org\/10.1038\/srep04026 (2014).","DOI":"10.1038\/srep04026"},{"key":"14122_CR11","doi-asserted-by":"publisher","unstructured":"Guo, Y., He, X., Tan, Y., Liu, J., Chen, H., Huang, Y. et al. ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis). J. Cancer Res. Clin. Oncol. 149, 15839\u201315844. https:\/\/doi.org\/10.1007\/s00432-023-05341-6 (2023).","DOI":"10.1007\/s00432-023-05341-6"},{"key":"14122_CR12","doi-asserted-by":"publisher","unstructured":"Yndestad, S., Engebrethsen, C., Herencia-Ropero, A., Nikolaienko, O., Vintermyr, O. K., Lillest\u00f8l, R. et al. Homologous recombination deficiency across subtypes of primary breast cancer. Jco Precis Oncol. https:\/\/doi.org\/10.1200\/po.23.00338 (2023).","DOI":"10.1200\/po.23.00338"},{"key":"14122_CR13","doi-asserted-by":"publisher","unstructured":"Mani\u00e9, \u00c9., Popova, T., Battistella, A., Tarabeux, J., Caux\u2010Moncoutier, V., Golmard, L. et al. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas. Int. J. Cancer. 138, 891\u2013900. https:\/\/doi.org\/10.1002\/ijc.29829 (2015).","DOI":"10.1002\/ijc.29829"},{"key":"14122_CR14","doi-asserted-by":"publisher","unstructured":"Mark, L. R.,.Terp, S. K., Krarup, H. B., Thomassen, M., Pedersen, I. S. & B\u00f8gsted, M. Homologous recombination deficiency detection algorithms: a systematic review. Cancers (Basel). 15, 5633. https:\/\/doi.org\/10.3390\/cancers15235633 (2023).","DOI":"10.3390\/cancers15235633"},{"key":"14122_CR15","doi-asserted-by":"publisher","unstructured":"Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517\u2013525. https:\/\/doi.org\/10.1038\/nm.4292 (2017).","DOI":"10.1038\/nm.4292"},{"key":"14122_CR16","doi-asserted-by":"publisher","unstructured":"Eeckhoutte, A., Houy, A., Mani\u00e9, E., Reverdy, M., Bi\u00e8che, I., Marangoni, E. et al. ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. Bioinformatics 36, 3888\u20133889. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa261 (2020).","DOI":"10.1093\/bioinformatics\/btaa261"},{"key":"14122_CR17","doi-asserted-by":"publisher","unstructured":"Sztupinszki, Z., Di\u00f3ssy, M., B\u00f6rcs\u00f6k, J., Pr\u00f3sz, A., Cornelius, N., Kjeldsen, M.K. et al. Comparative assessment of diagnostic homologous recombination deficiency\u2013associated mutational signatures in ovarian cancer. Clin. Cancer Res. 27, 5681\u20135687. https:\/\/doi.org\/10.1158\/1078-0432.ccr-21-0981 (2021).","DOI":"10.1158\/1078-0432.ccr-21-0981"},{"key":"14122_CR18","doi-asserted-by":"publisher","unstructured":"Golan, T., O\u2019Kane, G. M., Denroche, R. E., Raitses-Gurevich, M., Grant, R. C., Holter, S. et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology 160, 2119\u20132132e9. https:\/\/doi.org\/10.1053\/j.gastro.2021.01.220 (2021).","DOI":"10.1053\/j.gastro.2021.01.220"},{"key":"14122_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/ppo.0000000000000554","volume":"27","author":"TJ Brown","year":"2021","unstructured":"Brown, T. J. & Reiss, K. A. PARP inhibitors in pancreatic cancer. Cancer J. 27, 465\u2013475. https:\/\/doi.org\/10.1097\/ppo.0000000000000554 (2021).","journal-title":"Cancer J."},{"key":"14122_CR20","doi-asserted-by":"publisher","unstructured":"Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reutersw\u00e4rd, C., H\u00e4kkinen, J. et al. Whole-Genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat. Med. 25, 1526\u20131533. https:\/\/doi.org\/10.1038\/s41591-019-0582-4 (2019).","DOI":"10.1038\/s41591-019-0582-4"},{"key":"14122_CR21","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.3390\/cancers13184716","volume":"13","author":"MM Wattenberg","year":"2021","unstructured":"Wattenberg, M. M. & Reiss, K. A. Determinants of homologous recombination deficiency in pancreatic cancer. Cancers (Basel). 13, 4716. https:\/\/doi.org\/10.3390\/cancers13184716 (2021).","journal-title":"Cancers (Basel)"},{"key":"14122_CR22","doi-asserted-by":"publisher","unstructured":"Andersen, L. V. B., Larsen, M. J., Davies, H., Degasperi, A., Nielsen, H. R., Jensen, L. A. et al. Non-BRCA1\/BRCA2 high-risk Familial breast cancers are not associated with a high prevalence of BRCAness. Breast Cancer Res. 25, 69. https:\/\/doi.org\/10.1186\/s13058-023-01655-y (2023).","DOI":"10.1186\/s13058-023-01655-y"},{"key":"14122_CR23","unstructured":"Thomassen, M. Created in BioRender. (2024). https:\/\/biorender.com\/a66p512"},{"key":"14122_CR24","doi-asserted-by":"publisher","unstructured":"Larsen, M. J., Thomassen, M., Tan, Q., L\u00e6nkholm, A.-V., Bak, M., S\u00f8rensen, K. P. et al. RNA profiling reveals Familial aggregation of molecular subtypes in non-BRCA1\/2 breast cancer families. BMC Med. Genomics. 7, 9. https:\/\/doi.org\/10.1186\/1755-8794-7-9 (2014).","DOI":"10.1186\/1755-8794-7-9"},{"key":"14122_CR25","doi-asserted-by":"publisher","unstructured":"Parsons, M. T., de la Hoya, M., Richardson, M. E., Tudini, E., Anderson, M., Berkofsky-Fessler, W. et al. Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 variant curation expert panel. Am. J. Hum. Genet. 111, 2044\u20132058. https:\/\/doi.org\/10.1016\/j.ajhg.2024.07.013 (2024).","DOI":"10.1016\/j.ajhg.2024.07.013"},{"key":"14122_CR26","unstructured":"Li, H. & seqtk Github. (2023). https:\/\/github.com\/lh3\/seqtk (accessed July 16, 2024)."},{"key":"14122_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760. https:\/\/doi.org\/10.1093\/bioinformatics\/btp324 (2009).","journal-title":"Bioinformatics"},{"key":"14122_CR28","unstructured":"Eeckhoutte, A. ShallowHRD Github Repository. GitHub Repos 2024. https:\/\/github.com\/aeeckhou\/shallowHRD"},{"key":"14122_CR29","doi-asserted-by":"publisher","unstructured":"Scheinin, I., Sie, D., Bengtsson, H., van de Wiel, M. A., Olshen, A. B., van Thuijl, H. F., et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res. 24, 2022\u20132032. https:\/\/doi.org\/10.1101\/gr.175141.114 (2014).","DOI":"10.1101\/gr.175141.114"},{"key":"14122_CR30","doi-asserted-by":"publisher","unstructured":"Diossy, M., Reiniger, L., Sztupinszki, Z., Krzystanek, M., Timms, K. M., Neff, C. et al. Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann. Oncol. 29, 1948\u20131954. https:\/\/doi.org\/10.1093\/annonc\/mdy216 (2018).","DOI":"10.1093\/annonc\/mdy216"},{"key":"14122_CR31","unstructured":"Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O. et al. Scikit-learn: machine learning in python. J. Mach. Learn. Res. 12, 2825\u20132830 (2011)."},{"key":"14122_CR32","doi-asserted-by":"publisher","unstructured":"Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D. et al. SciPy 1.0: fundamental algorithms for scientific computing in python. Nat. Methods. 17, 261\u2013272. https:\/\/doi.org\/10.1038\/s41592-019-0686-2 (2020).","DOI":"10.1038\/s41592-019-0686-2"},{"key":"14122_CR33","unstructured":"Adel, L. & AUC_Boot-noBoot GitHub Repos. (2025). https:\/\/github.com\/LouiseAdel\/AUC_Boot-noBoot (accessed April 28, 2025)."},{"key":"14122_CR34","unstructured":"Stats (version 3.6.2). cor.test. RdocumentationOrg n.d. https:\/\/www.rdocumentation.org\/packages\/stats\/versions\/3.6.2\/topics\/cor.test (accessed June 20, 2025)."},{"key":"14122_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer. 16, 110\u2013120. https:\/\/doi.org\/10.1038\/nrc.2015.21 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"14122_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X. et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534, 47\u201354. https:\/\/doi.org\/10.1038\/nature17676 (2016).","journal-title":"Nature"},{"key":"14122_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nrc3181","volume":"12","author":"R Roy","year":"2011","unstructured":"Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer. 12, 68\u201378. https:\/\/doi.org\/10.1038\/nrc3181 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"14122_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11523-020-00756-4","volume":"15","author":"D Sigorski","year":"2020","unstructured":"Sigorski, D., I\u017cycka-\u015awieszewska, E. & Bodnar, L. Poly(ADP-Ribose) polymerase inhibitors in prostate cancer: Molecular mechanisms, and preclinical and clinical data. Target. Oncol. 15, 709\u2013722. https:\/\/doi.org\/10.1007\/s11523-020-00756-4 (2020).","journal-title":"Target. Oncol."},{"key":"14122_CR39","doi-asserted-by":"publisher","first-page":"e247811","DOI":"10.1001\/jamanetworkopen.2024.7811","volume":"7","author":"S Torres-Esquius","year":"2024","unstructured":"Torres-Esquius, S., Llop-Guevara, A., Guti\u00e9rrez-Enr\u00edquez, S., Romey, M., Teul\u00e9, \u00c0., Llort, G. et al. Prevalence of homologous recombination deficiency among patients with Germline RAD51C\/D breast or ovarian cancer. Jama Netw. Open. 7, e247811. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.7811 (2024).","journal-title":"Jama Netw. Open."},{"key":"14122_CR40","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1093\/nar\/gkw1204","volume":"45","author":"WA Reh","year":"2016","unstructured":"Reh, W. A., Nairn, R. S., Lowery, M. P. & V\u00e1squez, K. M. The homologous recombination protein RAD51D protects the genome from large deletions. Nucleic Acids Res. 45, 1835\u20131847. https:\/\/doi.org\/10.1093\/nar\/gkw1204 (2016).","journal-title":"Nucleic Acids Res."},{"key":"14122_CR41","doi-asserted-by":"publisher","unstructured":"Bueno-Mart\u00ednez, E., Sanoguera-Miralles, L., Valenzuela-Palomo, A., Lorca, V., G\u00f3mez-Sanz, A., Carvalho, S. et al. RAD51D aberrant splicing in breast cancer: Identification of splicing regulatory elements and minigene-based evaluation of 53 DNA variants. Cancers (Basel). 13, 2845. https:\/\/doi.org\/10.3390\/cancers13112845 (2021).","DOI":"10.3390\/cancers13112845"},{"key":"14122_CR42","doi-asserted-by":"publisher","unstructured":"Castroviejo-Bermejo, M., Cruz, C., Llop-Guevara, A., Guti\u00e9rrez-Enr\u00edquez, S., Ducy, M., Ibrahim, Y. H. et al. A RAD\u200951 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol. Med. 2018;10, e9172. https:\/\/doi.org\/10.15252\/emmm.201809172","DOI":"10.15252\/emmm.201809172"},{"key":"14122_CR43","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/cancers13051004","volume":"13","author":"MM Ladan","year":"2021","unstructured":"Ladan, M. M. & van Gent, D. C. Homologous recombination deficiency testing for BRCA-Like tumors: The road to clinical validation. Cancers (Basel). 13, 1004. https:\/\/doi.org\/10.3390\/cancers13051004 (2021).","journal-title":"Cancers (Basel)"},{"key":"14122_CR44","doi-asserted-by":"publisher","unstructured":"Spurdle, A. B., Healey, S., Devereau, A., Hogervorst, F. B. L., Monteiro, A. N. A., Nathanson, K. L. et al. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum. Mutat. 33, 2\u20137. https:\/\/doi.org\/10.1002\/humu.21628 (2012).","DOI":"10.1002\/humu.21628"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14122-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14122-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14122-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T09:02:11Z","timestamp":1754989331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14122-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14122"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14122-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and the Danish Ethical Committee System approved the study (The Regional Scientific Ethical Committees for Southern Denmark, case no. S-20220080, 11th of May 2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Informed consent was obtained from all subjects involved in the study using HRDetect. Patient consent regarding shallow sequencing and ShallowHRD was waived, as it is considered a study of quality assessment and validation, which according to the approval from the Regional Scientific Ethical Committees for Southern Denmark is exempted from informing the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"29442"}}